Compass Therapeutics (CMPX) Invested Capital (2018 - 2026)

Compass Therapeutics has disclosed Invested Capital across 9 years of filings, most recently posting $186.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $186.5 million, up 69.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $186.5 million (up 69.09% YoY), and the FY2025 annual result was $196.8 million, up 57.14% from the prior year.
• Invested Capital came in at $186.5 million for Q1 2026 at Compass Therapeutics, down from $196.8 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $209.6 million in Q3 2025 to a low of $93.2 million in Q2 2025.
• The 5-year median for Invested Capital is $148.5 million (2023), against an average of $151.4 million.
• Across the five-year window, Invested Capital surged 320.22% in 2022 and sank 36.21% in 2025, its largest moves.
• Compass Therapeutics' Invested Capital stood at $181.6 million in 2022, then dropped by 18.22% to $148.5 million in 2023, then fell by 15.69% to $125.2 million in 2024, then surged by 57.14% to $196.8 million in 2025, then fell by 5.24% to $186.5 million in 2026.
• The last three Invested Capital figures came in at $186.5 million (Q1 2026), $196.8 million (Q4 2025), and $209.6 million (Q3 2025), per Business Quant data.